Open for Enrollment Soon

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

NT101-AMD-001 (Age-Related Macular Degeneration) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called NT-101 (the study drug) is a safe and effective option for people with wet age-related macular degeneration (AMD). The study drug is a topical solution that is administered directly to the eye (eye drops).

What is the Condition Being Studied?

Wet Age-Related Macular Degeneration (AMD)

Who Can Participate in the Study?

Adults ages 50+ who:

Are diagnosed with wet AMD
Do not have diabetes
Do not have high blood pressure that is not controlled with medication

For more information about this study, contact the study team at DEC-RA@duke.edu.

Age Group

Adults

What is Involved?

If you choose to join the study, you will get a random assignment (like a coin flip) to 1 of 2 groups:

You will either get a 0.05 mM dose of the study drug; OR
You will get a 0.2 mM dose of the study drug

You will take the study drug twice each day for a period of 4 weeks.

Overall, participation in the study will last for about 8 weeks and will involve approximately 6 visits to the study clinic for exams and testing.

Study Details

Full Title

A Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD) - NT101-AMD-001

Principal Investigator